{"id":243,"title":"microRNA-614 contributes to recurrent miscarriage through targeting FOXD1","title_zh":"microRNA-614通过靶向FOXD1参与复发性流产","url":"https://pubmed.ncbi.nlm.nih.gov/42979824","doi":"10.1080/01443615.2026.2695781","pmid":"42979824","journal":"J Obstet Gynaecol","kind":"paper","lang":"en","published_at":"2026-11-04T00:00:00+00:00","fetched_at":"2026-11-08T03:44:00+00:00","authors":["Wan X","Che H","Lai L","Xiang S"],"primary_topic":"early-pregnancy","topics":[{"slug":"early-pregnancy","score":5.0,"hits":["pregnancy outcomes","recurrent miscarriage"]},{"slug":"contraception-health","score":2.0,"hits":["childbearing","reproductive health"]},{"slug":"endometrium","score":1.0,"hits":["trophoblast"]},{"slug":"ethics-policy","score":1.0,"hits":["regulation"]}],"topic_score":5.0,"preference_score":0.0,"preference_labels":[],"llm_score":74.0,"final_score":74.0,"score_dims":{"novelty":68,"rigor":78,"impact":70,"relevance":92,"translation":72},"recommend_reason":"研究提供了复发性流产的候选血浆生物标志物与FOXD1靶向机制，样本量尚可且实验验证较完整，值得关注；但诊断效能与机制结论仍需多中心、独立队列及体内实验验证。","keywords":["复发性流产","microRNA-614","FOXD1","滋养细胞","生物标志物","靶向调控"],"selected":1,"story_id":81,"llm_provider":"deepseek","llm_model":"deepseek-flash","llm_effort":"low","source_key":"pubmed-uterus-pregnancy","source_name":"PubMed · 内膜/植入/早孕","source_tier":1,"mention_count":1,"has_interpretation":false,"journal_key":null,"journal_tier":"unknown","journal_if":null,"is_mock":false,"summary_zh":"该研究基于GEO数据库筛选差异miRNA，并在135例复发性流产患者与135例健康对照中验证血浆miR-614表达及诊断效能；通过CCK-8、Transwell和双荧光素酶实验探讨其对滋养细胞增殖、侵袭、迁移及FOXD1靶向调控的作用。结果显示miR-614在RM中下调，诊断AUC为0.865，预测不良妊娠结局AUC为0.790；miR-614模拟物抑制HTR-8/JEG3细胞功能并负调控FOXD1。结论提示miR-614下调通过上调FOXD1促进RM发生。","summary":"OBJECTIVE: Recurrent miscarriage (RM) is a significant reproductive health issue affecting many women of childbearing age. The objective of this study was to evaluate the value of microRNA-614 (miR-614) as a potential biomarker for RM and to elucidate its functional mechanism. METHODS: Differentially expressed miRNAs (DEmiRs) were first screened from the Gene Expression Omnibus (GEO) database using a bioinformatics approach. A total of 135 patients with RM and 135 healthy controls were included. The expression levels and diagnostic performance of miR-614 were evaluated by RT-qPCR and ROC curve analysis. CCK-8 and Transwell were performed to assess the impact of the miRNA on trophoblast cell proliferation, invasion, and migration. For target gene verification, TargetScan 8.0 was utilised for prediction, followed by a luciferase activity assay to confirm direct regulation by miRNA. RESULTS: Bioinformatic interrogation of the GSE73025 dataset revealed a significant down-regulation of miR-614. Plasma miR-614 was significantly downregulated in RM patients. The area under the ROC curve (AUC) for miR-614 in distinguishing RM patients from controls was 0.865 (95% CI: 0.823-0.907, sensitivity = 77.78%, specificity = 77.78%). The AUC for predicting adverse pregnancy outcomes was 0.790 (95% CI: 0.708-0.870, sensitivity = 71.08%, specificity = 82.69%). Transfection with miR-614 mimics decreased the proliferation, invasion, and migration of HTR-8 and JEG3 cells. miR-614 Directly targets FOXD1 and negatively modulates its mRNA expression to drive RM progression. CONCLUSION: In RM patients, miR-614 is downregulated, leading to increased FOXD1 expression. miR-614 mimics suppresses trophoblast proliferation, migration, and invasion by directly targeting FOXD1. Thus, miR-614 downregulation contributes to RM pathogenesis by directly targeting FOXD1, thereby upregulating FOXD1 and inhibiting the proliferation, invasion, and migration of trophoblast cells.","interpretation_basis":null,"fulltext_status":null,"interpretation":null,"fulltext":{"available":false,"status":null,"reason":"尚未抓取全文（未入选、分数未达阈值，或还没跑 fulltext 步骤）","pmcid":null,"license":null,"chars":0,"source":null,"fetched_at":null}}